Autolus Therapeutics Net Income
| AUTL Stock | USD 1.43 0.03 2.05% |
As of the 12th of February 2026, Autolus Therapeutics shows the Risk Adjusted Performance of 0.0404, downside deviation of 5.14, and Mean Deviation of 3.85. Autolus Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Autolus Therapeutics variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Autolus Therapeutics is priced correctly, providing market reflects its regular price of 1.43 per share. Please also double-check Autolus Therapeutics total risk alpha, which is currently at (0.41) to validate the company can sustain itself at a future point.
Autolus Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 1.7014 | Revenue | Earnings Share (0.81) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -198.6 M | -188.7 M | |
| Net Loss | -134 M | -127.3 M | |
| Net Loss | -198.6 M | -188.7 M | |
| Net Loss | (0.99) | (1.04) | |
| Net Income Per E B T | 0.91 | 0.76 |
Autolus | Net Income | Build AI portfolio with Autolus Stock |
Historical Net Income data for Autolus Therapeutics serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Autolus Therapeutics represents a compelling investment opportunity.
Latest Autolus Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Autolus Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Autolus Therapeutics financial statement analysis. It represents the amount of money remaining after all of Autolus Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Autolus Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Autolus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (220.66 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Autolus Net Income Regression Statistics
| Arithmetic Mean | (94,094,876) | |
| Coefficient Of Variation | (84.40) | |
| Mean Deviation | 72,991,271 | |
| Median | (31,114,488) | |
| Standard Deviation | 79,419,618 | |
| Sample Variance | 6307.5T | |
| Range | 213.2M | |
| R-Value | (0.89) | |
| Mean Square Error | 1429.6T | |
| R-Squared | 0.79 | |
| Slope | (13,956,894) | |
| Total Sum of Squares | 100919.6T |
Autolus Net Income History
Other Fundumenentals of Autolus Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Autolus Therapeutics Net Income component correlations
Autolus Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Autolus Therapeutics is extremely important. It helps to project a fair market value of Autolus Stock properly, considering its historical fundamentals such as Net Income. Since Autolus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Autolus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Autolus Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Autolus Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.81) | Revenue Per Share | Quarterly Revenue Growth (0.11) | Return On Assets | Return On Equity |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Autolus Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Autolus Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Autolus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Autolus Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Autolus Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Autolus Therapeutics.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Autolus Therapeutics on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Autolus Therapeutics or generate 0.0% return on investment in Autolus Therapeutics over 90 days. Autolus Therapeutics is related to or competes with Solid Biosciences, QuantumSi, Rocket Pharmaceuticals, LB Pharmaceuticals, ADC Therapeutics, Neumora Therapeutics, and RAPT Therapeutics. Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of can... More
Autolus Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Autolus Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Autolus Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.14 | |||
| Information Ratio | 0.0205 | |||
| Maximum Drawdown | 30.76 | |||
| Value At Risk | (6.29) | |||
| Potential Upside | 10.45 |
Autolus Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Autolus Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Autolus Therapeutics' standard deviation. In reality, there are many statistical measures that can use Autolus Therapeutics historical prices to predict the future Autolus Therapeutics' volatility.| Risk Adjusted Performance | 0.0404 | |||
| Jensen Alpha | (0) | |||
| Total Risk Alpha | (0.41) | |||
| Sortino Ratio | 0.0208 | |||
| Treynor Ratio | 0.0926 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Autolus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Autolus Therapeutics February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0404 | |||
| Market Risk Adjusted Performance | 0.1026 | |||
| Mean Deviation | 3.85 | |||
| Semi Deviation | 4.73 | |||
| Downside Deviation | 5.14 | |||
| Coefficient Of Variation | 2479.49 | |||
| Standard Deviation | 5.21 | |||
| Variance | 27.19 | |||
| Information Ratio | 0.0205 | |||
| Jensen Alpha | (0) | |||
| Total Risk Alpha | (0.41) | |||
| Sortino Ratio | 0.0208 | |||
| Treynor Ratio | 0.0926 | |||
| Maximum Drawdown | 30.76 | |||
| Value At Risk | (6.29) | |||
| Potential Upside | 10.45 | |||
| Downside Variance | 26.37 | |||
| Semi Variance | 22.39 | |||
| Expected Short fall | (4.44) | |||
| Skewness | 0.0244 | |||
| Kurtosis | 1.62 |
Autolus Therapeutics Backtested Returns
As of now, Autolus Stock is risky. Autolus Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0389, which signifies that the company had a 0.0389 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Autolus Therapeutics, which you can use to evaluate the volatility of the firm. Please confirm Autolus Therapeutics' Downside Deviation of 5.14, risk adjusted performance of 0.0404, and Mean Deviation of 3.85 to double-check if the risk estimate we provide is consistent with the expected return of 0.19%. Autolus Therapeutics has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 2.16, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Autolus Therapeutics will likely underperform. Autolus Therapeutics right now shows a risk of 4.88%. Please confirm Autolus Therapeutics value at risk, as well as the relationship between the skewness and day median price , to decide if Autolus Therapeutics will be following its price patterns.
Auto-correlation | -0.78 |
Almost perfect reverse predictability
Autolus Therapeutics has almost perfect reverse predictability. Overlapping area represents the amount of predictability between Autolus Therapeutics time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Autolus Therapeutics price movement. The serial correlation of -0.78 indicates that around 78.0% of current Autolus Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.78 | |
| Spearman Rank Test | -0.64 | |
| Residual Average | 0.0 | |
| Price Variance | 0.05 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Autolus Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Autolus Therapeutics reported net income of (220.66 Million). This is 164.66% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 138.65% higher than that of the company.
Autolus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Autolus Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Autolus Therapeutics could also be used in its relative valuation, which is a method of valuing Autolus Therapeutics by comparing valuation metrics of similar companies.Autolus Therapeutics is currently under evaluation in net income category among its peers.
Autolus Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Autolus Therapeutics from analyzing Autolus Therapeutics' financial statements. These drivers represent accounts that assess Autolus Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Autolus Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 460.9M | 374.1M | 1.1B | 599.6M | 689.6M | 749.9M | |
| Enterprise Value | 361.0M | 131.8M | 933.6M | 424.9M | 488.6M | 552.3M |
Autolus Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Autolus Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Autolus Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Autolus Therapeutics' value.| Shares | Axa Sa | 2025-06-30 | 3.1 M | Affinity Asset Advisors, Llc | 2025-06-30 | 3 M | T. Rowe Price Associates, Inc. | 2025-06-30 | 2.7 M | Renaissance Technologies Corp | 2025-06-30 | 1.8 M | Atle Fund Management Ab | 2025-06-30 | 1.1 M | Citadel Advisors Llc | 2025-06-30 | 1 M | Bank Of America Corp | 2025-06-30 | 975.1 K | Jpmorgan Chase & Co | 2025-06-30 | 914.7 K | Perpetual Ltd | 2025-06-30 | 829.1 K | Wellington Management Company Llp | 2025-06-30 | 27.1 M | Blackstone Inc | 2025-06-30 | 20.5 M |
Autolus Fundamentals
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (3.38) % | ||||
| Current Valuation | 79.01 M | ||||
| Shares Outstanding | 266.14 M | ||||
| Shares Owned By Insiders | 5.56 % | ||||
| Shares Owned By Institutions | 73.17 % | ||||
| Number Of Shares Shorted | 15.44 M | ||||
| Price To Earning | (19.33) X | ||||
| Price To Book | 1.46 X | ||||
| Price To Sales | 7.44 X | ||||
| Revenue | 10.12 M | ||||
| Gross Profit | (135.38 M) | ||||
| EBITDA | (233.07 M) | ||||
| Net Income | (220.66 M) | ||||
| Cash And Equivalents | 216.44 M | ||||
| Cash Per Share | 2.38 X | ||||
| Total Debt | 52.63 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 7.29 X | ||||
| Book Value Per Share | 1.00 X | ||||
| Cash Flow From Operations | (206.27 M) | ||||
| Short Ratio | 5.04 X | ||||
| Earnings Per Share | (0.81) X | ||||
| Target Price | 9.32 | ||||
| Number Of Employees | 647 | ||||
| Beta | 1.99 | ||||
| Market Capitalization | 380.58 M | ||||
| Total Asset | 782.73 M | ||||
| Retained Earnings | (1.1 B) | ||||
| Working Capital | 600.19 M | ||||
| Current Asset | 102.22 M | ||||
| Current Liabilities | 6.46 M | ||||
| Net Asset | 782.73 M |
About Autolus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Autolus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Autolus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Autolus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Autolus Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.81) | Revenue Per Share | Quarterly Revenue Growth (0.11) | Return On Assets | Return On Equity |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Autolus Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Autolus Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Autolus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.